May 14, 2026/
Three persistent myths continue to shape how pharmaceutical companies, biotechs, and even some regulators approach pharmacovigilance (PV), and each one carries a multi-million-dollar price tag.
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
Three persistent myths continue to shape how pharmaceutical companies, biotechs, and even some regulators approach pharmacovigilance (PV), and each one carries a multi-million-dollar price tag.
Safety recommendations for two medicinal products: the CAR-T cell therapy axicabtagene ciloleucel (Yescarta) and the tyrosine kinase inhibitor ponatinib (Iclusig).
World Hand Hygiene Day, observed annually on 5 May, has for 18 years championed the single most effective measure to prevent healthcare-associated infections (HAIs): timely and...
